Daniel J Zinn, Olive Eckstein, Mary L Olsen, Carl E Allen, Kenneth L McClain
{"title":"沙利度胺:治疗多中心网状组织细胞增多症的合理药物。","authors":"Daniel J Zinn, Olive Eckstein, Mary L Olsen, Carl E Allen, Kenneth L McClain","doi":"10.35248/2684-124X.19.4.152","DOIUrl":null,"url":null,"abstract":"<p><p>A patient with Multifocal Reticulohistiocytosis (MRH) of skin and joints failed treatment with etanercept, methotrexate, hydroxychloroquine, prednisone, bisphosphonates and hydroxyzine. Long term treatment with thalidomide led to marked improvement in joint and cutaneous manifestations.</p>","PeriodicalId":92997,"journal":{"name":"Dermatology case reports","volume":"4 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a1/24/nihms-1024550.PMC7289025.pdf","citationCount":"2","resultStr":"{\"title\":\"Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis.\",\"authors\":\"Daniel J Zinn, Olive Eckstein, Mary L Olsen, Carl E Allen, Kenneth L McClain\",\"doi\":\"10.35248/2684-124X.19.4.152\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>A patient with Multifocal Reticulohistiocytosis (MRH) of skin and joints failed treatment with etanercept, methotrexate, hydroxychloroquine, prednisone, bisphosphonates and hydroxyzine. Long term treatment with thalidomide led to marked improvement in joint and cutaneous manifestations.</p>\",\"PeriodicalId\":92997,\"journal\":{\"name\":\"Dermatology case reports\",\"volume\":\"4 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2019-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a1/24/nihms-1024550.PMC7289025.pdf\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Dermatology case reports\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.35248/2684-124X.19.4.152\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2019/4/8 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology case reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.35248/2684-124X.19.4.152","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2019/4/8 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}
Thalidomide, A Rational Agent for Treatment of Multicentric Reticulohistiocytosis.
A patient with Multifocal Reticulohistiocytosis (MRH) of skin and joints failed treatment with etanercept, methotrexate, hydroxychloroquine, prednisone, bisphosphonates and hydroxyzine. Long term treatment with thalidomide led to marked improvement in joint and cutaneous manifestations.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
